Probability of biochemical recurrence by analysis of pathologic stage, Gleason score, and margin status for localized prostate cancer
- PMID: 14624910
- DOI: 10.1016/s0090-4295(03)00674-5
Probability of biochemical recurrence by analysis of pathologic stage, Gleason score, and margin status for localized prostate cancer
Abstract
Objectives: The Partin tables provide pretreatment information regarding the probability of various pathologic stages (eg, organ confined, extraprostatic extension, and seminal vesicle or lymph node involvement). Although the pathologic stage serves as an excellent surrogate for outcome after radical prostatectomy (RRP), many patients and physicians want to know how the predictions made from the Partin tables can be translated into long-term biochemical recurrence-free survival. In this work, we go beyond the pathologic outcomes predicted by the Partin nomograms to provide long-term biochemical recurrence-free estimates on the basis of the pathologic data obtained at RRP to help counsel patients after surgery for prostate cancer.
Methods: The study group comprised 1955 men treated by one surgeon with RRP and pelvic lymph node dissection for clinically localized disease (1989 to 2001). The patients were followed up for at least 1 year postoperatively, and the disease-free survival rates were determined using Kaplan-Meier analysis.
Results: The pathologic stages were as follows: organ confined in 57%, extraprostatic extension in 35%, seminal vesicle involvement in 4%, and lymph node involvement in 4%. The prostatectomy Gleason score distribution was as follows: 2 to 4 in 1%, 5 to 6 in 63%, 7 in 30%, and 8 to 10 in 6%. Overall, a positive surgical margin was present in 9.8%. On the basis of the prostatectomy Gleason score, pathologic stage, and surgical margin status, the probability of long-term biochemical recurrence-free survival was divided into four groups: excellent, good, moderate, and low.
Conclusions: These simple to use and explain risk groups can be used to predict long-term biochemical recurrence-free survival from pathologic stage data obtained at surgery or predicted from the Partin tables, along with surgical margin status and Gleason score information obtained at RRP.
Similar articles
-
Role of microvessel density in predicting recurrence in pathologic Stage T3 prostatic adenocarcinoma.Urology. 1999 Sep;54(3):479-85. doi: 10.1016/s0090-4295(99)00202-2. Urology. 1999. PMID: 10475358 Clinical Trial.
-
Stage T1-2 prostate cancer: a multivariate analysis of factors affecting biochemical and clinical failures after radical prostatectomy.Int J Radiat Oncol Biol Phys. 1997 Mar 15;37(5):1043-52. doi: 10.1016/s0360-3016(96)00590-1. Int J Radiat Oncol Biol Phys. 1997. PMID: 9169811
-
Long-term cancer control of radical prostatectomy in men younger than 50 years of age: update 2003.Urology. 2003 Jul;62(1):86-91; discussion 91-2. doi: 10.1016/s0090-4295(03)00404-7. Urology. 2003. PMID: 12837428
-
No difference in six-year biochemical failure rates with or without pelvic lymph node dissection during radical prostatectomy in low-risk patients with localized prostate cancer.Urology. 2004 Mar;63(3):528-31. doi: 10.1016/j.urology.2003.09.064. Urology. 2004. PMID: 15028451 Review.
-
Long-term biochemical disease-free and cancer-specific survival following anatomic radical retropubic prostatectomy. The 15-year Johns Hopkins experience.Urol Clin North Am. 2001 Aug;28(3):555-65. doi: 10.1016/s0094-0143(05)70163-4. Urol Clin North Am. 2001. PMID: 11590814 Review.
Cited by
-
Impact of surgical margin status on prostate-cancer-specific mortality.BJU Int. 2012 Dec;110(11):1684-9. doi: 10.1111/j.1464-410X.2012.11371.x. Epub 2012 Jul 12. BJU Int. 2012. PMID: 22788795 Free PMC article.
-
Cancer/testis antigens: novel tools for discerning aggressive and non-aggressive prostate cancer.Asian J Androl. 2012 May;14(3):400-4. doi: 10.1038/aja.2011.144. Epub 2012 Feb 20. Asian J Androl. 2012. PMID: 22343492 Free PMC article. Review.
-
The emergence of radioimmunoscintigraphy for prostate cancer.Rev Urol. 2006;8 Suppl 1(Suppl 1):S20-8. Rev Urol. 2006. PMID: 17021623 Free PMC article.
-
Altered metabolism and mitochondrial genome in prostate cancer.J Clin Pathol. 2006 Jan;59(1):10-6. doi: 10.1136/jcp.2005.027664. J Clin Pathol. 2006. PMID: 16394275 Free PMC article. Review.
-
Pharmacoeconomics of available treatment options for metastatic prostate cancer.Pharmacoeconomics. 2007;25(4):309-27. doi: 10.2165/00019053-200725040-00004. Pharmacoeconomics. 2007. PMID: 17402804 Review.
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Medical